C26 Stock Chart & Stats
€16.36
-€0.36(-1.99%)
At close: 4:00 PM EST
€16.36
-€0.36(-1.99%)
Day’s Range― - ―
52-Week Range€10.64 - €17.06
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€318.13M
Enterprise Value€3.13K
Total Cash (Recent Filing)€230.22M
Total Debt (Recent Filing)€22.43M
Price to Earnings (P/E)26.2
Beta0.68
Next Earnings
Oct 29, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.62
Shares Outstanding23,851,547
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.58Price Target Upside-17.02% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.56
Revenue Forecast (FY)€70.31M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a strong equity base provide durable financial flexibility. This reduces refinancing and solvency risk, lets management fund R&D, product launches and dividends from internal resources, and better absorbs regional or cyclical shocks over the next 2–6 months.
High, Resilient MarginsSustained high gross and operating margins reflect pricing power, recurring software/reagent mix and efficient instrument economics. Durable margin structure supports reinvestment, covers fixed costs, and preserves earnings quality even if revenue growth softens, underpinning long-term profitability.
Product Pipeline & Commercial TractionCommercial BMA launch, targeted US 510(k) and an advancing FPM platform expand the addressable market and product stickiness. Coupled with outsized Americas instrument wins, this signals structural growth levers and deeper installed-base recurring revenue potential over the medium term.
Bears Say
Weakened Free-cash-flow ConversionA sharp drop in FCF conversion vs prior year suggests higher capex, working-capital build or timing effects. Persistently lower cash conversion would reduce self-funding capacity for R&D, dividends or bolt-on investments and increase dependence on the balance sheet if structural.
Regional And Channel ExposureNotable APAC weakness and distributor inventory effects in EMEA highlight geographic and channel concentration risks. Reliance on uneven regional demand and third-party distribution can produce volatile quarterly growth and makes medium-term top-line recovery contingent on resolving these structural market issues.
Working-capital Pressure And Cash OutflowsA quarter of rising receivables/inventory and negative total cash flow (despite solid operating results) shows liquidity strain from working-capital swings and cash distributions. If persistent, this can constrain operational flexibility, slow reinvestment or force external funding for growth initiatives.
CellaVision AB News
C26 FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was €10.64 and its highest was €17.06 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is €318.13M.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Oct 29, 2026 which is in 102 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Jul 17, 2026. The company reported €0.124 earnings per share for the quarter, beating the consensus estimate of €0.121 by €0.003.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB does not currently pay dividends.
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 0.13.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of €0.124 in its last earnings report, beating expectations of €0.121. Following the earnings report the stock price went up 0.828%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in DE:C26
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
C26 Stock 12 Month Forecast
Average Price Target
€13.58
▼(-17.02% Downside)
Technical Analysis
BICO Group AB Class B
―
Senzime AB
―
Xvivo Perfusion AB
―
C-Rad AB Class B
―
Sedana Medical AB
―